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Abstract 
Background: This systematic review and meta-analysis summarized the most recent evidence on the efficacy of 
intermittent energy restriction (IER) versus continuous energy restriction on weight-loss, body composition, blood 
pressure and other cardiometabolic risk factors.
Methods: Randomized controlled trials were systematically searched from MEDLINE, Cochrane Library, TRIP data-
bases, EMBASE and CINAHL until May 2018. Effect sizes were expressed as weighted mean difference (WMD) and 95% 
confidence intervals (CI).
Results: Eleven trials were included (duration range 8–24 weeks). All selected intermittent regimens provided ≤ 25% 
of daily energy needs on “fast” days but differed for type of regimen (5:2 or other regimens) and/or dietary instructions 
given on the “feed” days (ad libitum energy versus balanced energy consumption). The intermittent approach deter-
mined a comparable weight-loss (WMD: − 0.61 kg; 95% CI − 1.70 to 0.47; p = 0.87) or percent weight loss (WMD: 
− 0.38%, − 1.16 to 0.40; p = 0.34) when compared to the continuous approach. A slight reduction in fasting insulin 
concentrations was evident with IER regimens (WMD = − 0.89 µU/mL; − 1.56 to − 0.22; p = 0.009), but the clinical 
relevance of this result is uncertain. No between-arms differences in the other variables were found.
Conclusions: Both intermittent and continuous energy restriction achieved a comparable effect in promoting 
weight-loss and metabolic improvements. Long-term trials are needed to draw definitive conclusions.
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Background
In the last decade, much interest has been focused on 
dietary strategies that manipulate energy intake uncon-
ventionally, known as intermittent fasting or intermit-
tent energy restriction (IER) [1–4]. This dietary approach 
has gained greater attention and popularity as a way for 
losing weight alternative to the conventional weight-loss 
diets, characterized by continuous (non-intermittent) 
energy restriction (CER). The two most popular forms 
of IER are: the 5:2 diet characterized by two consecu-
tive or non-consecutive “fast” days and the alternate-day 
energy restriction, commonly called alternate-day fast-
ing, alternate-day modified fasting, or every-other-day 
fasting, consisting of a ‘‘fast” day alternated with a ‘‘feed” 
day [5]. Commonly, during “fast” days, the energy intake 
is severely restricted, ranging from complete abstinence 
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from foods to a daily maximum intake roughly corre-
sponding to 75% energy restriction. Therefore, the term 
“fast” often does not involve a true complete abstinence 
from caloric intake. The term IER will be used to describe 
all intermittent energy-restricted/fasting regimens.
The time-restricted feeding [2, 6–9] and the very-low-
calorie or energy diets [2, 3] are other types of dietary 
interventions which were often included in previous sys-
tematic reviews and meta-analyses on IER. Indeed, in the 
former, individuals are allowed to eat within a specific 
range of time, thus, every day there is a period without 
food intake, varying from 12 to 21  h [10–12] (i.e. the 
Muslim Ramadan). On the other hand, there is no daily 
intermittency in a very-low-calorie-diet, although the 
overall energy intake may be similar to those of the IER 
regimens [13].
To the best of our knowledge, an overall evaluation of 
the impact of IER on multiple metabolic variables, on 
percent body fat changes, and on the effects of balanced 
versus ad libitum “feed” days, as well as on the benefits of 
the different “fasting” regimens is at present lacking.
The primary objective of this systematic review and 
meta-analysis was to update the efficacy of IER on weight 
loss, limiting the analyses to regimens which actually 
included a weekly intermittent energy restriction, i.e. 
from 1 up to 6 “fast days” per week. Furthermore, the 
impact of IER on fat mass (FM), fat free mass (FFM), 
arterial blood pressure (BP) and other cardiometabolic 
risk factors was assessed. The effects of IER according to 
the specific type of nutritional regimen on all these out-
comes were evaluated too.
Materials and methods
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines in 
the reporting of this study [14].
Search strategy
The following electronic databases were queried using 
a combination of search terms until the 31th of May 
2018: PubMed (National Library of Medicine), the TRIP 
database, the Cochrane Library, EMBASE, and Cumu-
lative Index to Nursing and Allied Health Literature 
(CINAHL). The construction of the search strategy was 
performed using database specific subject headings and 
keywords. Both medical subject headings (MeSH) and 
free text search terms were employed. Restrictions to 
human studies were placed.
The search terms included combinations of “inter-
mittent fasting” or “alternate day fasting” or “intermit-
tent energy restriction” or “periodic fasting”, and weight 
loss, weight gain, obesity, weight, fat mass, blood pres-
sure, blood glucose, insulin, insulin-resistance, insulin 
sensitivity, glycated hemoglobin A1c (HbA1c), type 2 
diabetes mellitus (T2DM), cholesterol, and triglycerides 
(free-term and MESH as possible) (Additional file  1). 
These search strategies were implemented by hand 
searching the references of all the included studies and 
systematic reviews on the field.
Study selection
We included studies with the following characteristics: 
(1) randomized controlled trials (RCTs); (2) a detailed 
description of the IER regimen; (3) 75% of energy 
restriction on “fast” days, with a maximum cut-off of 
500/660  kcal/day for females/males, respectively; (4) 
weekly intermittency of energy restriction (from 1 up to 6 
“fast” days per week); (5) trial duration > 4 weeks; (6) con-
taining as comparator a group on a CER regimen and (7) 
including changes in body weight or percent body weight 
as one of the study’s outcome.
We excluded studies with the following characteris-
tics: (i) uncontrolled trials or study design other than 
RCTs; (ii) studies not including body weight as an out-
come and/or lacking sufficient information on weight 
change; (iii) including time restricted feeding interven-
tion; (iv) reporting very-low-calorie or fasting regimens 
for > 6  days consecutive/week; and (v) providing > 500–
660 kcal/day or not reporting the amount of calorie pre-
scribed on “fast” days.
In trials with multiple interventional arms (i.e. exercise 
arm, intervention arm with specific diets), the IER and 
the CER arms were considered, while other arms were 
not analyzed, since out of the scope of this review.
Two authors (IC, SB) separately screened abstracts 
for their inclusion or exclusion; retrieving full text arti-
cles from potentially relevant abstracts. Any discrepancy 
about inclusion was resolved by discussing with a third 
author (AE).
Outcomes
The primary outcome of the review was evaluating 
changes in body weight or in percent body weight. Sec-
ondary outcomes were: changes in body mass index 
(BMI), waist circumference, FM, FFM, arterial BP, and 
the blood values of fasting glucose and insulin, insu-
lin resistance, insulin sensitivity, HbA1c, total choles-
terol, HDL- and LDL-cholesterol, and triglycerides. The 
changes of these outcomes according to the specific type 
of IER regimen were also evaluated.
Data collection and extraction
From each included study, the following informa-
tion were extracted (1) first author name and year of 
publication; (2) study design; (3) inclusion criteria of 
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participants; (4) trial duration; (5) number of subjects 
enrolled in each arm; (6) type of dietary intervention; 
(7) age, gender, BMI of participants; (8) body composi-
tion (FM and FFM); (9) systolic (SBP) and diastolic blood 
pressure (DBP); (10) blood concentrations of fasting glu-
cose, HbA1c, insulin, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, and triglycerides; (11) Homeostasis 
Model Assessment-Insulin Resistance (HOMA-IR) and 
insulin-sensitivity index (Si).
Risk of bias assessment
All studies were independently assessed by two authors 
(IC, SB) using the “Risk of bias” tool developed by the 
Cochrane Collaboration for RCTs [15]. The items used 
for the assessment of each study were the following: ade-
quacy of sequence generation, allocation concealment, 
blinding, addressing of dropouts (incomplete outcome 
data), selective outcome reporting, and other potential 
sources of bias. A judgment of “L” indicated low risk of 
bias, “H” indicated high risk of bias, and “unclear” indi-
cated an unclear/unknown risk of bias. The possible 
disagreements were resolved by consensus, or with con-
sultation with a third author (AE).
Data synthesis
Data synthesis was performed only for the outcomes 
which were reported by > 3 trials.
The pooled effect sizes were expressed as weighted 
mean differences (WMD) and 95% confidence interval 
(CI) between IER and CER arms of the mean outcome 
values measured at the end of follow-up.
The mean difference of changes from baseline was esti-
mated for each study on the basis of reported baseline 
and follow-up measurements. If the standard deviation 
for change from baseline was not reported, we imputed 
missing values assuming a within-patient correlation 
from baseline to follow-up measurements of 0.8 as sug-
gested in the Cochrane handbook [16]. When between-
arms mean differences on change from baseline were 
already estimated [17], those data were included. For the 
relative weight change from baseline, the non-reported 
standard deviations were imputed using the mean stand-
ard deviation of the available studies.
Random-effects models were applied to provide a sum-
mary estimate.
Inter-study heterogeneity was assessed using Cochrane 
Q statistic and quantified by  I2 test [18].
Subgroup analyses for all outcomes were performed 
based on the different dietary regimen of the “feed” days 
(balanced vs. ad  libitum food intake) and the effects 
of the different regimens of “fasting” (5:2 vs. the other 
regimens). Weighting of studies was done using generic 
inverse variance method.
In order to evaluate the influence of each study on the 
overall effect size, sensitivity analysis was conducted 
using the one-study remove (leave-one-out) approach.
Potential publication bias was explored using visual 
inspection funnel plot asymmetry and Egger’s weighted 
regression tests.
Meta-analyses were performed by using the Stata 
Metan package (Stata Statistical Software, Release 13; 
StataCorp LP, College Station, TX); meta-regressions 
and Egger’s weighted regression tests for publication bias 
were performed using the metafor package (version 1.9-
7) for R (version 3.1.2, R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
Included studies
The initial literature search identified 8577 records. After 
removing duplicates, 6943 records were screened, and, 
after excluding articles not meeting the inclusion crite-
ria, 94 records were assessed for eligibility. After further 
analysis and quality assessment, a total of 11 studies were 
selected for the systematic review and meta-analysis 
(Fig.  1). All studies identified were RCTs, reporting an 
IER arm and a CER arm comparison; the corresponding 
details are shown in Table 1. Data relative to participants 
involved in exercise-only arms [19] or in high-protein 
dietary intervention [20] were not considered, because 
not pertinent to the aims of the study.
Characteristics of the studies
The total number of subjects included in the present 
analysis was 630 at enrolment. During the course of the 
trials, 102 patients dropped out. Drop-out rates ranged 
from about 2% [21] to 38% for IER arms [22] and from 
0% [23] to 50% [22] for CER. The number of participants 
analyzed at the end of the RCTs was 528.
There was a greater number of women among partici-
pants, with the exception of 3 studies with a balanced 
number between men and women [21, 22, 24] and 1 
enrolling only men [23]. Participants were individuals 
with overweight/obesity; in 2 RCTs patients with T2DM 
were selected [23, 25], and in 1 RCT patients with mul-
tiple dysmetabolic conditions were enrolled [21]. In all 
RCTs except for 2 [23, 25], participants with a stable 
weight before the beginning of the study, without his-
tory of bariatric surgery, and without drugs impacting on 
weight or the other study outcomes, were studied.
Trials were performed in UK [20, 22, 26], in USA [17, 
19, 25, 27], in Australia [23, 24], and Norway [21, 28]. 
The duration of the studies ranged from 8 weeks [27] to 
24 weeks [17, 21, 23, 26].
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Dietary intervention
Four studies prescribed alternating “fast” and “feed” 
days [17, 19, 27, 28]. Six studies used 2 “fast” days and 5 
“feed” days per week (5:2 diet) [21–24, 26]. In 1 RCT, 5 
consecutives “fast” days were prescribed before a 1 “fast” 
day/week regimen per 15 weeks in the IER arm, while the 
other arm (5 “fast” days every 5 weeks) was not consid-
ered, since no intermittence within the same week was 
present [25]. On “fast” days, diets provided a maximum 
of 660 kcal/day. In 2 studies, participants were instructed 
to consume their meals between 12:00 p.m. and 2:00 p.m. 
on “fast” days to ensure that subjects underwent the same 
duration of fasting [17, 19]. In 4 studies, meals of “fast” 
days were partially [17, 25] or totally supplied [19, 27]. 
In 1 study, a commercially available very-low energy for-
mula-based food was assigned in the “fast” days [22].
On “feed” days, 6 studies prescribed healthy and bal-
anced eating pattern, according to the energy require-
ments [17, 20, 22, 25, 26, 28], 4 allowed for ad  libitum 
food intake based on the participants’ usual eating 
[19, 21–24] and 1 provided a diet based on the energy 
requirements but allowing the access to 5–7 optional 
food modules (200  kcal each) [27]. In the comparator 
arms, energy was restricted by approximately 25% of the 
daily energy requirements in all studies (CER arms).
Dietary compliance and energy intake assessment
Six studies specifically assessed the compliance to the 
diet and the overall energy intake in both arms by filling 
7-day food records at different time points [17, 20–22, 26, 
28]. In 1 study, dieticians evaluated adherence by using 
patients’ self-recorded dietary diaries and diet histories 
taken during their dietetic appointments [23]. Either 
similar adherence between IER and CER [20, 21, 23, 26, 
28], a lower [17] or a higher [22] adherence in the IER 
arms were reported. Adherence to the recommenda-
tions in the IER arms ranged from 64% [26] to 93% [22] 
at the end of the RCTs, but data were difficult to compare 
because of their incompleteness and the different meth-
ods employed to evaluate the compliance.
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Risk of bias assessment
Some of the analyzed trials were characterized by the 
lack of information about the randomization procedures 
(Additional file 2). If blinding of participants was not fea-
sible owing to the nature of the interventions, data about 
blinding of the personnel performing the laboratory or 
statistical analyses were always unknown, except for 1 
study [20]. Dropouts were higher in the IER arms [17, 26, 
28] or in the CER arms [20, 22, 24, 25], thus introducing 
a possible selection bias between-arms, but intention-to 
treat analyses were performed by all studies, except for 1 
RCT [22], where data of the completers only have been 
reported. Finally, most trials appeared to be free of selec-
tive outcome reporting and of other sources of bias, apart 
from 1, where body weight at baseline was not reported 
[19].
Meta-analysis
All the outcomes of interest of this systematic review 
are reported in Additional file 3. Data synthesis was per-
formed for the outcomes reported by > 3 trials, therefore 
data relative to Si values were not pooled.
Weight loss
All RCTs reported weight loss in the IER arms during the 
intervention, ranging from 5.2% [19] of initial weight to 
12.9% [28], while in the CER arms, changes ranged from 
4.3% [20] to 12.1% [28] (Additional file  3). Pooled data 
from random-effect analysis did not show a significant 
effect of IER on weight loss (WMD: −  0.61  kg, 95% CI 
− 1.70 to 0.47; p = 0.27) (Fig. 2). The estimated effect on 
body weight did not change in the leave-one-out sensitiv-
ity analysis (data not shown).
Subgroup analyses based on the type of regimen (5:2 
vs. other regimens) as well as on the dietary character-
istics of the “feed” days of the IER interventions (ad libi-
tum vs. balanced food intake) showed consistent results, 
as reported in Additional file 4. Analyses were repeated 
after the exclusion of the trial prescribing 5 consecutives 
“fast” days and then 1 “fast” day/week per 15 weeks [25], 
and the results did not change (WMD: − 0.36 kg, 95% CI 
−  1.48 to 0.77; p = 0.54). Finally, the RCT reporting the 
percent relative variations of the endpoints only [19] was 
included in the analyses, and the estimated effect size of 
weight change did not show any between-arms difference 
(WMD: − 0.08, 95% CI − 0.23 to 0.07; p = 0.29).
Similarly, the percent weight loss was similar in both 
arms (WMD: − 0.38%, 95% CI − 1.16 to 0.40; p = 0.34) 
and the results did not differ either in the subgroup anal-
yses (Additional file 5) or in the leave-one-out sensitivity 
analysis.
Other anthropometric measures
Seven out of the 11 included RCTs reported changes in 
FM and FFM [17, 20, 22, 24, 26–28]. FM was measured 
by different methods: body impedance analysis (BIA) 
[20, 22]; dual X-ray absorptiometry (DXA) [17, 24, 27]; 
impedance [26]; air displacement plethysmography [28]. 
Pooled results showed no difference between-arms in 
FM (WMD: − 0.23 kg, 95% CI − 1.23 to 0.77; p = 0.66) as 
well as in FFM (WMD: − 0.22 kg, 95% CI − 1.01 to 0.56; 
p = 0.58), as shown in Additional file  6. Those results 
were consistent both at subgroup analyses and at sensi-
tivity analyses. Five RCTs assessed waist circumference 
[20–23, 26] without showing any differences between 
arms (WMD: − 0.17 cm; 95% CI − 1.74 to 1.39; p = 0.83).
Cardiometabolic biomarkers
Pooled data obtained from glucose, HbA1c, insulin 
and HOMA-IR are presented in Fig.  3a–d respectively. 
Changes in fasting glucose and HbA1c values were 
reported respectively in 7 [17, 20–23, 26, 27] and 4 [21, 
24–26] trials. Random-effect analysis showed no dif-
ference either on glucose (WMD: −  0.49  mg/dL, 95% 
CI − 1.98 to 0.99; p = 0.51) or HbA1c (WMD: − 0.02%, 
95% CI − 0.10 to 0.06; p = 0.62) changes in the IER when 
compared to CER arms with consistent results in sub-
group/sensitivity analyses.
On the contrary, fasting insulin values were signifi-
cantly reduced with IER (WMD = −  0.89 µU/mL; 95% 
CI − 1.56 to − 0.22; p = 0.009;  I2 = 0%) and the estimated 
effect appeared robust in the leave-one-out sensitivity 
analysis (data not shown). Moreover, subgroup analy-
ses showed that the 5:2 regimens were associated with 
increased insulin reductions (WMD: − 0.99 µU/mL; 95% 
CI − 1.67 to − 0.30; p = 0.005;  I2 = 0) (Additional file 7). 
All the RCTs evaluating fasting insulin values included 
a balanced energy regimen for the “feed” days. HOMA-
IR values were reduced, though not significantly, in the 
IER regimens (WMD = − 0.15 mmol/L × µU/mL; 95% CI 
− 0.33 to 0.02; p = 0.09).
Only 1 RCT evaluated insulin sensitivity (Si) by a fre-
quently sampled intravenous glucose tolerance [21], 
without between-arms differences.
Pooled data obtained from 8 RCTs [17, 20–23, 25–27] 
did not show any significant effect of IER on triglyc-
eride concentrations (WMD: −  3.11  mg/dL, 95% CI 
−  9.76 to 3.54; p = 0.36) (Fig.  4a). However, subgroup 
analyses showed a slightly significant triglyceride reduc-
tion in the IER arms employing other fasting regi-
mens (WMD = − 14.4 mg/dL 95% CI − 28.6 to − 0.23; 
p = 0.046;  I2 = 0%). Characteristics of the “feed” days were 
not associated with differences in triglyceride changes 
(Additional file 8). HDL-cholesterol levels increased after 
IER regimens, albeit not significantly (WMD = 1.72 mg/
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dL 95% CI −  0.20 to 3.63; p = 0.07) (Fig.  4c). Subgroup 
analysis revealed a significant HDL-cholesterol increase 
with a balanced diet on “feed” days (WMD = 2.88  mg/
dL 95% CI 0.66 to 5.09; p = 0.011;  I2 = 0%) compared with 
ad  libitum eating (Additional file  9). No between-arm 
differences were found for total cholesterol and LDL-
cholesterol (Fig. 4b, d). Finally, changes in both SBP and 
DBP did not significantly differ between arms (Additional 
file 10).
Publication bias
We used the Egger’s test for funnel plot asymmetry to 
detect a potential publication bias on reporting results on 
weight change. Test result (p = 0.15) did not suggest any 
asymmetry in the funnel plot (Additional file 11).
Safety
No major adverse events were reported. Only 1 patient 
from the IER arm of the RCT supplying 0  kcal during 
“fast” days developed gallbladder dyskinesia and under-
went cholecystectomy after completing the study, but 
this event was reported to be unrelated to the interven-
tion [27]. Minor physical or psychological adverse effects, 
such as lack of energy, headaches, feeling cold, constipa-
tion, bad breath, lack of concentration, bad temper, were 
reported in a minority of participants from the IER arms 
(< 20%) in a few studies [20, 21, 23, 26]. On the other 
hand, hunger was reported in the first weeks by about 
half of participants to a 5:2 regimen in 1 trial, but this 
symptom improved over time [23].
Discussion
An intermittent regimen of energy restriction (at least 
1  day/week) determined a loss in body weight and per-
cent body weight similar to continuous (non-intermit-
tent) energy restriction. Interestingly, a slight reduction 
in fasting insulin concentrations was evident with IER 
regimens employing 2  days/week “fast”, but the clinical 
relevance of this result is uncertain.
Effects of IER on weight loss and fat mass
Most systematic reviews and meta-analyses demon-
strated that IER regimens achieved comparable weight 
loss as CER regimens [4, 5, 9], reporting an overall weight 
loss ranging from 4 to 8% [2, 3, 7, 9], and a difference of 
− 4.14 kg to + 0.08 kg versus the comparator arms [4, 5, 
29]. Our results are in accordance, even if the trials previ-
ously included differed from ours, since we have included 
only RCTs with a at least 1 day/week and no more than 
6 day/week of “fasting”, and with an extremely low energy 
supply during the “fast” days. This latter choice derived 
from the idea of studying conditions simulating as much 
as possible a condition of fasting, whose benefits, proven 
by animal studies, seem to depend on the shift in metab-
olism from glucose utilization and fat synthesis/storage 
towards reduced insulin secretion and fat mobilization/
oxidation [30, 31].
There is no clear definition of IER, and intermittent 
regimens providing up to 800  kcal [5, 9], with ≥ 7 “fast” 
days [4, 6, 9, 29], including time-restricted feeding [2, 
6–8, 32], with unlimited energy restriction as a compara-
tor group [2, 3, 5–7], or not randomized controlled trials 
[2] have been included within previous reviews. We have 
taken care to define precise inclusion criteria to limit var-
iability and increase the comparability among trials, and 
we have obtained a low heterogeneity.
It could be hypothesized that the very low caloric 
intake on “fast” days determined an overall lower 
caloric intake in the IER arms, which were therefore 
difficult to be compared with the CER arms. In the 
only RCT where water and calorie-free beverages were 
allowed in the “fast” days, a significant between-arms 
difference in energy intake was evident [27]; in two 
studies a between-arms difference of 300–400 kcal was 
observed [22, 23] while most RCTs reported a negligi-
ble between-arms difference (~ 100 kcal) [17, 20, 21, 25, 
26]. Consistently, our sensitivity and subgroup analyses 
did not find significant between-arms differences.
Furthermore, the percent weight loss was highly 
overlapping, and no apparent superiority of a dietary 
regimen was evident. Indeed, participants of the IER 
arms from all RCTs lost ≥ 5% of their initial weights, 
thus confirming the clinical usefulness of this approach 
at least in the short term, i.e. within 24 weeks.
Previous reviews reported a FM loss ranging from 4 
to 7% [3] to 11–16% [2] in the IER arms, and the only 
meta-analysis evaluating this outcome reported a dif-
ferential loss of 1.38  kg with respect to comparator 
arms [5]. We failed to find significant between-arms 
difference for this outcome, suggesting that such a regi-
men could be a valid, but not superior alternative to 
CER.
Intriguingly, participants to the IER regimens usually 
did not consume as much food in the “feed” days as to 
compensate for the caloric restriction of the “fast” days, 
thus suggesting that IER could reduce food intake even 
in the “feed” days, without compensatory overeating [6, 
31]. This finding was not confirmed by all studies [28, 
33, 34]. Furthermore, adverse events were sometimes 
higher with the IER regimens [20, 21, 26], and the partici-
pants reported stronger feelings of hunger [21, 23]. The 
compliance and adherence to the intervention diets was 
heterogeneous among trials, the attrition rate was often 
higher in the IER arms [17, 22, 24, 26, 31, 35], and the 
percentage of participants planning to continue with the 
dietary regimen beyond 6 months was lower in the IER 
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arms [26]. Overall, these data do not support the fact that 
IER is easier and more acceptable than CER to everyone. 
Moreover, the reduction in resting energy expenditure, 
i.e. the compensatory metabolic response which reduces 
the degree of weight loss, has been reported to be either 
reduced (favoring weight loss) [27, 36] or increased 
(attenuating weight loss) [22, 28] with IER regimens. 
Indeed, some studies suggest that IER evokes the same 
adaptive response as CER [6, 37].
The hypothesized benefits of IER, extensively studied 
in animal models, included the use of fats during severe 
energy restriction with preferential reduction of adipose 
mass, the stimulation of browning in white adipose tis-
sue, increased insulin sensitivity, lowering of leptin and 
increased human growth hormone, ghrelin and adi-
ponectin circulating levels, reduced inflammation and 
oxidative stress [30]. The trigger of adaptive cell response 
leading to enhanced ability to cope with stress, improved 
autophagy by sirtuin-1 activity stimulation, modification 
of apoptosis, increase of vascular endothelial growth fac-
tor expression in white adipose tissue, the action on the 
metabolism via Forkhead Box A genes, and reduction 
of advance glycation end-products might be all possible 
metabolic pathways explaining the beneficial effects of 
IER [7, 30, 38, 39]. In mice, IER determined metabolic 
improvements and weight loss as a consequence of a shift 
in the gut microbiota composition, leading to an increase 
in the production of acetate and lactate and to the selec-
tive upregulation of monocarboxylate transporter in 
beige adipose cells which stimulate beige fat thermogen-
esis [40]. At present, many of these adaptive mechanisms 
have been demonstrated in animal experimental models 
but not in humans, thus more research is still needed.
Effects of IER on cardiometabolic markers
IER regimens were associated with lower circulating 
insulin values; a significant reduction was evident for 
the 5:2 “fasting” regimen only. Indeed, two RCTs, both 
employing this regimen, determined the difference [20, 
26]. Our data are in line with the results of a previous 
meta-analysis reporting a significantly higher reduction 
in fasting insulin (−  0.67 µU/mL) in the IER arms [5]. 
The difference we found (− 0.89 µU/mL) was statistically 
significant, but not clinically relevant, above all consider-
ing the fact that participants to the included RCTs were 
overweight/obese and therefore probably insulin-resist-
ant individuals.
Our data synthesis on glucose, HOMA-IR, HbA1c 
showed no between-arms difference. We did not include 
patients with T2DM from 2 RCTS in the pooled analy-
sis on fasting glucose, since most participants were on 
hypoglycemic drugs and their glycemic values would be 
Fig. 2 Meta-analysis of the effects of intermittent energy restriction versus continuous energy restriction on weight loss. MD (mean difference) 
indicates the mean difference on change from baseline of the IER vs. the CER arms. The plotted points are the mean differences and the horizontal 
error bars represent the 95% confidence intervals. The grey areas are proportional to the weight of each study in the random-effects meta-analysis. 
The vertical dashed line represents the pooled point estimate of the mean difference. The solid black line indicates the null hypothesis (MD = 0)
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certainly influenced by the treatment [24, 25]. Highly 
contrasting human studies are available about the ben-
efits of IER on glucose metabolism and insulin sensitivity 
[3, 6, 31], contrarily to animal studies strongly suggesting 
a benefit in T2DM prevention [1, 31]. The improvements 
in glucose homeostasis might be therefore comparable to 
those obtained by continuous energy restrictions.
Our meta-analysis did not show significant between-
arms difference in lipid values and arterial blood pres-
sure, with the exception of a small difference in subgroup 
analyses on triglyceride concentrations (− 14 mg/dL) and 
HDL-cholesterol (+ 2.88 mg/dL), not meaningful from a 
clinical point of view. Most studies showed reduction in 
triglyceride levels between 15 and 42% in the IER arms 
[31, 41], and the only available meta-analysis reported 
a between-arms not significant difference of 2.65  mg/
dL [5]. Reduction in total cholesterol, LDL-cholesterol 
in the IER arms ranged respectively between 6–25%, 
7–32%, with small effects on HDL-cholesterol [1, 31], 
and between-arms differences resulted not significant 
[5]. Intriguingly, a few studies reported that IER regimens 
determined an increase in LDL particle size [19, 42], and 
reduced post-prandial hypertriglyceridemia [22], thus 
potentially conferring cardio-protection, since the lower 
the LDL size, the higher the oxidizability and the suscep-
tibility to arterial penetration, and higher post-prandial 
hyperlipemia is a marker of atherosclerosis progression. 
Furthermore, fasting can act on many enzymes impli-
cated in lipid and lipoprotein metabolism [27]. How-
ever, all these reports need confirmation in larger human 
RCTs.
Similarly, data on arterial BP were controversial, with 
the majority of human studies reporting no differences 
between IER and CER regimens [1, 5, 31, 41]. Indeed, 
most of the published studies and RCTs included normo-
tensive subjects at baseline, making it difficult to identify 
differences between-arms.
Therefore, unlike the very promising data on animals, 
evidence is not sufficiently robust to suggest the superi-
ority of intermittent vs. continuous caloric restriction 
regimens on the main cardiovascular factors in humans.
Fig. 3 Meta-analysis of the effects of intermittent energy restriction versus continuous energy restriction on fasting glucose (a), HbA1c (b), insulin 
(c) and HOMA-IR (d) values. MD (mean difference) indicates the mean difference on change from baseline of the IER vs. the CER arms. The plotted 
points are the mean differences and the horizontal error bars represent the 95% confidence intervals. The grey areas are proportional to the weight 
of each study in the random-effects meta-analysis. The vertical dashed line represents the pooled point estimate of the mean difference. The solid 
black line indicates the null hypothesis (MD = 0)
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Clinical implications
Weight loss maintenance should be an integral compo-
nent of the management of obesity, owing to the weight 
regain usually occurring with time. The 2 RCTs includ-
ing longer follow-ups (24 months) did not find between-
arms differences in weight loss maintenance [17, 27]. 
Studies with longer follow-ups, evaluating the long-
term sustainability, adherence to, and safety of IER regi-
mens are needed. Furthermore, no RCT evaluated hard 
endpoints, such as cardiovascular outcomes or T2DM 
incidence. Two observational cohort studies found that 
fasting was associated with a lower prevalence of coro-
nary artery diseases or diabetes diagnosis but are limited 
by a lack of a comprehensive dietary history and many 
potential bias [43, 44]. It could be hypothesized that IER 
regimens should be proposed in clinical practice, since 
it is possible that some individuals find easier to reduce 
their energy intakes for 1 or more days per week, rather 
than every day. It is well known that a single diet fit not 
all, and in the choice of the individual’s tailored regimen, 
IER strategies should be considered by health care pro-
fessionals. In this way, data on the feasibility of these regi-
mens in “real life” would be obtained.
Strengths and limitations
This is, to our knowledge, the largest and updated meta-
analysis on the effects of IER on weight loss and multiple 
metabolic outcomes, setting strict inclusion criteria to 
increase comparability among studies.
The high variability among the RCTs in the feeding 
protocols, the limited follow-up, the small sample sizes, 
the high drop-out rates potentially leading to selection 
bias, the limited reporting of adverse events and blind-
ing of investigators about arm allocation, or other meth-
odological problems are all limitations to be considered. 
Finally, most studies were performed by the same authors 
and the majority of subjects included were adult healthy 
women, thus limiting the generalizability of the results.
Fig. 4 Meta-analysis of the effects of intermittent energy restriction versus continuous energy restriction on triglycerides (a), total cholesterol (b), 
HDL-cholesterol (c) and LDL-cholesterol (d) values. MD (mean difference) indicates the mean difference on change from baseline of the IER vs. the 
CER arms. The plotted points are the mean differences and the horizontal error bars represent the 95% confidence intervals. The grey areas are 
proportional to the weight of each study in the random-effects meta-analysis. The vertical dashed line represents the pooled point estimate of the 
mean difference. The solid black line indicates the null hypothesis (MD = 0)
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Conclusion
In overweight/obese adults, IER is as effective as CER 
for promoting weight loss and metabolic improvements 
in the short term. Further long-term investigations are 
needed to draw definitive conclusions.
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